878207-92-2

Usage

Uses

Used in Pharmaceutical Industry:
6-CHLORO-3-METHYL-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER is used as a key building block for the development of new drugs and medications, contributing to the advancement of pharmaceutical formulations and therapeutic agents.
Used as a Laboratory Reagent:
In the laboratory setting, 6-CHLORO-3-METHYL-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER serves as a valuable reagent, facilitating various chemical reactions and processes in research and development.
Used in Organic Synthesis:
6-CHLORO-3-METHYL-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER is utilized as an intermediate in the production of a range of organic compounds, playing a crucial role in the synthesis of complex molecules and specialty chemicals.
Safety Precautions:
Due to its flammable nature, 6-CHLORO-3-METHYL-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER requires careful handling and storage to prevent accidents and ensure the safety of those working with the compound.

InChI:InChI=1/C8H8ClNO2/c1-5-3-4-6(9)10-7(5)8(11)12-2/h3-4H,1-2H3

Upstream product

• 67-56-1 methanol 
• 1201924-32-4 6-chloro-3-methyl-pyridine-2-carboxylic acid 
• 59718-84-2 3-methyl-pyridine-2-carboxylic acid methyl ester 
• 1201924-31-3 6-chloro-3-methyl-pyridine-2-carbonitrile 
• 159727-88-5 3-methyl-1-oxido-pyridin-1-ium-2-carbonitrile 
• 20970-75-6 2-cyano-3-methylpyridine 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 878207-91-1 methyl 3-methyl-1-oxido-pyridin-1-ium-2-carboxylate 

Downstream Products

• 1201924-34-6 methyl 3-(bromomethyl)-6-chloropicolinate 
• 1400664-29-0 C₂₇H₂₉N₃O₄ 
• 1400664-24-5 C₂₇H₂₉N₃O₄ 
• 1400664-30-3 C₂₆H₂₆ClN₃O₃ 
• 1400664-31-4 C₂₆H₂₆ClN₃O₃ 
• 1400664-26-7 C₂₆H₂₆ClN₃O₃ 
• 1400664-32-5 C₂₆H₂₆FN₃O₃ 
• 1400664-27-8 C₂₆H₂₆FN₃O₃ 
• 1400664-17-6 C₂₇H₂₆F₃N₃O₃ 
• 1400664-35-8 C₂₇H₂₆N₄O₃ 
• 1400664-07-4 C₂₇H₂₉N₃O₃ 
• 1400664-23-4 C₂₇H₂₉N₃O₃ 
• 1400664-09-6 C₂₈H₃₁N₃O₃ 
• 1400664-10-9 C₂₈H₃₁N₃O₃ 

Relevant academic research and scientific papers

INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION

Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

DIMETHYLBENZOIC ACID COMPOUNDS

The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.

SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. (I)

SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

Disclosed are compounds of formula (I) that are useful as hepatitis C virus (HCV) NSSB polymerise inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NSSB polymerise activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Synthesis and SAR study of pyrrolo[3,4-b]pyridin-7(6H)-one derivatives as melanin concentrating hormone receptor 1 (MCH-R1) antagonists

The discovery and optimization of novel pyrrolo[3,4-b]pyridin-7(6H)-one MCH-R1 antagonists are described. A systematic SAR study probing the effects of aryl-, benzyl- and arylthio-substituents at the 2-position of the pyrrolo[3,4-b]pyridin-7(6H)-ones led to identification of the 2-[(4-fluorophenyl)thio] derivative 7b as a highly potent MCH-R1 antagonist. This compound also has favorable pharmacokinetic properties along with a high metabolic stability and a minimal impact on CYP isoforms and hERG.

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS

The invention provides compounds of formula (I) pharmaceutically acceptable salt or solvate thereof, in which R1, A1, m and A are as defined in the specification; a process for their preparation; pharmaceutical compositions containin